Clinical trials: Paramyxoviridae Infections
Epidemic Parotitis, Mumps
Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11
Mumps is an acute infectious respiratory disease caused by the mumps virus (MuV), which occurs mainly in children and adolescents. Its main clinical symptoms were parotid gland suppurative swelling and pain with fever.
- Trial name
- NCT04591405
- Testing
- Attenuated Mumps vaccine (KMB-17) in phase II and III, Attenuated Mumps vaccine (KMB-17) in phase III
- Where
- China
- Volunteers
- 11,999 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
HIV Infections, Measles
A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group
To compare measles seroconversion rates (development of antibodies) at 13 months of age in HIV-infected and uninfected children on one of two immunization schedules: attenuated measles/mumps/rubella virus (M-M-R II) vaccine at 12…
- Trial name
- NCT00000815
- Testing
- Attenuvax, M-M-R-II
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
This study is being to see how effective and safe ALS-008176 is in treating adults in the hospital with a Respiratory Syncytial Virus-Related Illness.
- Trial name
- NCT02673476
- Testing
- ALS-008176
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 9 people
- Sponsor
- Alios Biopharma Inc.
Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection
- Trial name
- NCT06817889
- Testing
- Remdesivir, Survey Administration, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV…
- Trial name
- NCT06389487
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 52 sites in United States, Australia and 4 more
- Volunteers
- 1,459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parainfluenza
An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.
- Trial name
- PIV (NCT01924793)
- Testing
- DAS181-F02 Dry Powder in Bulk, DAS181-F02 Nebulized Formulation Inhaled Dose
- Where
- 23 sites in United States
- Volunteers
- 23 people
- Sponsor
- Ansun Biopharma, Inc.
Severe Respiratory Syncytial Virus Infection
Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease
Retrospective medical record review study of specific adverse events in children with congenital heart disease who received palivizumab for prophylaxis of serious respiratory syncytial virus infection and control subjects that…
- Trial name
- NCT01075178
- Where
- 37 sites in Austria, Belgium and 8 more
- Volunteers
- 2,036 people
- Sponsor
- Abbott
Respiratory Syncytial Virus Infections
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among…
- Trial name
- NCT00129766
- Testing
- motavizumab (MEDI-524), palivizumab
- Where
- 344 sites in United States, Argentina and 22 more
- Volunteers
- 6,635 people
- Sponsor
- MedImmune LLC
Respiratory Syncytial Virus Infections
Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults
In this randomised, placebo-controlled, double-blind Phase 2a study, healthy male and female participants 18-50 years of age will be given an investigational RSV vaccine (RSVpreF) and challenged with RSV one month later.
- Trial name
- NCT04785612
- Testing
- RSVPreF
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hvivo
Respiratory Syncytial Virus Infections, Antibiotic Stewardship in Community Hospitals
RSV Antibiotic Drivers And Resource-use
This study retrospectively evaluated the clinical, laboratory, and radiologic factors that influence the decision to prescribe antibiotics in children under 2 years of age hospitalized with RSV-positive acute lower respiratory…
- Trial name
- RADAR (NCT06977971)
- Where
- Turkey (Türkiye)
- Volunteers
- 209 people
- Sponsor
- Dr. Behcet Uz Children's Hospital
Measles
Measles Vaccination Cash Incentives Experimental Evidence From Nigeria
IDinsight is conducting a randomized controlled trial to assess the impact of various sized cash incentives for caretakers of infants that require a 9-month measles vaccination on the completion rate for the vaccine in Nigeria.
- Trial name
- NCT04013516
- Testing
- Cash Incentive, Call
- Where
- Nigeria
- Volunteers
- 1,088 people, healthy volunteers welcome
- Sponsor
- IDinsight
Varicella, Measles
Safety Study of a Refrigerator-stable Formulation of VARIVAX®
Primary objective: To describe the safety profile of a refrigerator-stable formulation of VARIVAX® as a first single dose injection in 12 to 15 month-old infants in the 42-day follow-up period post-vaccination.
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432731
- Testing
- VARIVAX®, M-M-RTM II
- Where
- 25 sites in France, Italy
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Syncytial Virus Infections
Anti-RSV Study in Chinese Patients (ASCENT)
This is a randomised, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered AK0529 in Chinese adults with RSV infection.
- Trial name
- ASCENT (NCT03699202)
- Testing
- AK0529
- Where
- 22 sites in China
- Volunteers
- 1 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
RSV Infection
A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV
This is a randomized, double-blind, placebo-controlled Phase Ib/IIa study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of XW001 inhalation in children with RSV infection in China
- Trial name
- NCT05779995
- Testing
- XW001
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
RSV Infection
Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
A longitudinal observational study based on routinely collected data on hospital and health care use for RSV infections will be undertaken.
- Trial name
- NIRSE-GAL (NCT06180993)
- Testing
- Nirsevimab
- Where
- Spain
- Volunteers
- 42,000 people
- Sponsor
- Federico Martinón Torres
Nipah Virus Infection
Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
Background: Nipah virus (NiV) is transmitted from animals to humans, from humans to humans, and through contaminated food. Infected people may have a cough and trouble breathing.
- Trial name
- NCT05398796
- Testing
- mRNA -1215
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
RSV Infection, Bronchiolitis
Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study
The fraction of exhaled nitric oxide (feNO) in expired air is a reliable measure of airway inflammation. Some research experiments have demonstrated stimulation of nitric oxide production in respiratory epithelial cells infected…
- Trial name
- NCT01090557
- Testing
- Collection of exhaled breath
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Winthrop University Hospital
Respiratory Syncytial Virus Infections
A Study of AK0529 in Adults Patients Hospitalized With RSV Infection
This is a randomized, double-blind, placebo-controlled, multicenter, phase II study to be conducted in adults hospitalized with RSV infection in China.
- Trial name
- NCT06942299
- Testing
- AK0529
- Where
- 42 sites in China
- Volunteers
- 25 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
RSV Infection
Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults
Gates MRI-RSM01-101 was a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, occurrence of Anti-drug antibody (ADA), and assessment of…
- Trial name
- NCT05118386
- Testing
- RSM01
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Measles
Ontogeny of Measles Immunity in Infants
This is an immunogenicity study evaluating the development of the immune response of healthy infants following primary vaccination with Attenuvax at 6 or 9 months of age compared with responses in 12 month-old infants receiving…
- Trial name
- NCT00240916
- Testing
- Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous), MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)
- Where
- 2 sites in United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Stanford University